US EditionSanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
Sanofi will acquire Dynavax for $2.2 billion to add the adult hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 to its portfolio, targeting a large unvaccinated adult population.
- Sanofi agreed to acquire Dynavax Technologies for about $2.2 billion, offering $15.50 per share in cash, with the deal subject to regulatory approval.
- Sanofi is pursuing the deal to strengthen adult immunization by adding Dynavax's marketed vaccine and the shingles candidate Z-1018, marking its second vaccines buy this year after the Vicebio acquisition.
- HEPLISAV-B's two-dose, one-month regimen sets it apart, with Dynavax reporting $268.4 million in 2024 sales and 46% market share .
- The Dynavax board of directors unanimously approved the transaction, the tender offer has not yet commenced, and shareholders are urged to review tender offer materials and related SEC filings.
- Sanofi said the agreement would not affect its 2025 outlook, and completion is subject to customary closing conditions including an HSR waiting period and foreign filings; it will fund the acquisition with available cash resources.
33 Articles
33 Articles
Why Dynavax Stock Soared Today
Key PointsSanofi is launching an all-cash tender offer for Dynavax's shares.The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price.10 stocks we like better than Dynavax Technologies › Shares of Dynavax Technologies (NASDAQ: DVAX) popped on Wednesday after the vaccine maker struck a deal to be acquired by Sanofi (NASDAQ: SNY). As of 3:00 p.m. EST, Dynavax's stock price was up more than 38%.Where to invest $1,00…
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition
Dynavax Technologies brings Sanofi a commercialized hepatitis B vaccine and a clinical-stage shingles vaccine, both of which offer differentiation from products marketed by GSK. It’s Sanofi’s second billion-dollar vaccines acquisition of 2025. The post Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition appeared first on MedCity News.
Sanofi To Commence Cash Tender Offer To Acquire Dynavax For $15.50/share
(RTTNews) - Sanofi (SNY, SAN.PA) has entered into an agreement to acquire Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine and differentiated shingles vaccine candidate. Sanofi will commence a cash tender offer to acquire all outs
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine.
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
